Lexaria Bioscience Corp. (NASDAQ: LEXX), a Global
Post# of 421
(Total Views: 234)
Posted On: 03/10/2022 4:45:26 PM
Lexaria Bioscience Corp. (NASDAQ: LEXX), a Global Innovator in Drug Delivery Platforms
- Lexaria’s patented DehydraTECH technology proved effective for sildenafil delivery in animal study PDE5-A21-1
- The company also made some notable strides with its HYPER-H21-4 clinical study on hypertension and heart disease treatment using DehydraTECH-CBD
- By doing so, it hopes to capitalize on the growing cardiovascular drugs market, which is projected to be valued at $107.8 billion by 2025 (https://nnw.fm/arzaT)
- With the success of its studies thus far, the company seeks to conduct even more trials over the 2022 calendar year
Lexaria Bioscience (NASDAQ: LEXX) has, since its inception, remained committed to enhancing the speed and efficiency of orally-delivered fat-soluble active molecules and drugs. Through its patented DehydraTECH(TM) drug delivery technology that began development in 2014, the company is offering potential solutions for conditions including, but not limited to hypertension, smoking cessation, anti-viral treatments, and other drug classes.
In what has marked a landmark achievement for Lexaria, its DehydraTECH technology proved effective for sildenafil delivery in an animal study conducted on lab rats. In addition, the study demonstrated that this technology offered improved treatment of erectile dysfunction, a condition that, according to estimates, will affect about 322 million men worldwide by 2025 (https://nnw.fm/qsqgS).
When compared to the most common sildenafil product- Viagra, Lexaria’s alternative proved to be more effective, with a delivery of 74% more sildenafil into the bloodstream on average than the concentration-matched, generic control formulation. For reference, Viagra is only moderately bioavailable orally at about 40%, with most people citing its slowness to act as a primary complaint.
Lexaria has also made incredible developments with its HYPER-H21-4 clinical study on hypertension and heart disease treatment using DehydraTECH-CBD. Given the success of previous studies, the company also announced plans for more trials over the year 2022.
“During 2021, we completed research & development (‘R&D’) and validating work equal to or greater than all the combined amount previously completed since 2018!” noted Chris Bunka, the Chief Executive Officer (“CEO”) of Lexaria.
“We have conducted studies across broad areas of interest but also concentrated in specific areas where we have had supportive data,” he added (https://nnw.fm/HgzJX).
For 2022, the company is focusing on DehydraTECH-processed-CBD for potential heart disease and hypertension treatment. Mr. Bunka also noted that from April (or sooner), the company should kick off what it terms as its largest-ever hypertension study.
“If this study is successful, we feel strongly that it will be highly supportive of our IND filing plan, and we will have a clear path toward designing of Phase 1 and even potentially Phase II FDA-registered clinical studies thereunder. Assuming there are no major delays either in study execution or evaluation, we expect full results from this study sometime in Q3, 2022,” noted Mr. Bunka.
These strides stamp Lexaria’s position as a global innovator in drug delivery platforms. But, more importantly, they seek to create value for shareholders while also positioning the company for growth as time progresses. Lexaria looks to capitalize on this growth and is, therefore, investing heavily into its R&D to introduce new treatments and receive regulatory approval for existing ones.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Lexaria’s patented DehydraTECH technology proved effective for sildenafil delivery in animal study PDE5-A21-1
- The company also made some notable strides with its HYPER-H21-4 clinical study on hypertension and heart disease treatment using DehydraTECH-CBD
- By doing so, it hopes to capitalize on the growing cardiovascular drugs market, which is projected to be valued at $107.8 billion by 2025 (https://nnw.fm/arzaT)
- With the success of its studies thus far, the company seeks to conduct even more trials over the 2022 calendar year
Lexaria Bioscience (NASDAQ: LEXX) has, since its inception, remained committed to enhancing the speed and efficiency of orally-delivered fat-soluble active molecules and drugs. Through its patented DehydraTECH(TM) drug delivery technology that began development in 2014, the company is offering potential solutions for conditions including, but not limited to hypertension, smoking cessation, anti-viral treatments, and other drug classes.
In what has marked a landmark achievement for Lexaria, its DehydraTECH technology proved effective for sildenafil delivery in an animal study conducted on lab rats. In addition, the study demonstrated that this technology offered improved treatment of erectile dysfunction, a condition that, according to estimates, will affect about 322 million men worldwide by 2025 (https://nnw.fm/qsqgS).
When compared to the most common sildenafil product- Viagra, Lexaria’s alternative proved to be more effective, with a delivery of 74% more sildenafil into the bloodstream on average than the concentration-matched, generic control formulation. For reference, Viagra is only moderately bioavailable orally at about 40%, with most people citing its slowness to act as a primary complaint.
Lexaria has also made incredible developments with its HYPER-H21-4 clinical study on hypertension and heart disease treatment using DehydraTECH-CBD. Given the success of previous studies, the company also announced plans for more trials over the year 2022.
“During 2021, we completed research & development (‘R&D’) and validating work equal to or greater than all the combined amount previously completed since 2018!” noted Chris Bunka, the Chief Executive Officer (“CEO”) of Lexaria.
“We have conducted studies across broad areas of interest but also concentrated in specific areas where we have had supportive data,” he added (https://nnw.fm/HgzJX).
For 2022, the company is focusing on DehydraTECH-processed-CBD for potential heart disease and hypertension treatment. Mr. Bunka also noted that from April (or sooner), the company should kick off what it terms as its largest-ever hypertension study.
“If this study is successful, we feel strongly that it will be highly supportive of our IND filing plan, and we will have a clear path toward designing of Phase 1 and even potentially Phase II FDA-registered clinical studies thereunder. Assuming there are no major delays either in study execution or evaluation, we expect full results from this study sometime in Q3, 2022,” noted Mr. Bunka.
These strides stamp Lexaria’s position as a global innovator in drug delivery platforms. But, more importantly, they seek to create value for shareholders while also positioning the company for growth as time progresses. Lexaria looks to capitalize on this growth and is, therefore, investing heavily into its R&D to introduce new treatments and receive regulatory approval for existing ones.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)